Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature

Song,Lei; Pan,Dejian; Zhou,Rengui

doi:10.3892/mco.2020.2124

Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature

Authors:
- Lei Song
- Dejian Pan
- Rengui Zhou
View Affiliations

Affiliations: Department of Hematology and Oncology, The 904 Hospital of The PLA (Chinese People's Liberation Army), Wuxi, Jiangsu 214044, P.R. China
Published online on: August 24, 2020 https://doi.org/10.3892/mco.2020.2124
Article Number: 54
Copyright: © Song et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The main therapeutic strategy for metastatic Myxofibrosarcoma (MFS) is palliative chemotherapy. A number of studies have demonstrated that anti‑angiogenic therapy and immunotherapy could improve the survival rate of patients with metastases. However, the effectiveness of the combination of anti‑angiogenic therapy and immunotherapy for the therapy of MFS is undetermined. The current study reports a case of metastatic myxofibrosarcoma that was treated with combination Nivolumab (monoclonal antibody, PD‑1 inhibitor) and Bevacizumab (monoclonal antibody, anti‑VEGF) after progression from the single use of Nivolumab. The aim of the current study is to assess the efficacy and safety of Nivolumab and Bevacizumab for metastatic myxofibrosarcoma and to review the literature. Up to the termination of the follow‑up, the patient achieved a partial response for 16 months, had an overall survival for over 29 months since the metastasis and demonstrated a sustained benefit from treatment. The most frequent adverse events were fatigue, abnormality of Alanine aminotransferase (ALT), hypertension and proteinuria. Nivolumab and Bevacizumab treatment indicate beneficial clinical effects and are indicated to be safe to use in patients with metastatic myxofibrosarcoma.

View Figures

View References

1	Angervall L, Kindblom LG and Merk C: Ayxofibrosarcoma: A study of 30 cases. Acta Pathol Microbiol Scand A. 85A:127–140. 1977.PubMed/NCBI
2	Fletcher CD, Bridge JA, Hogendoorn PC, et al: WHO classifitation of tumours of soft tissue and bone. Lyon, IARC Press, 93-94, 2013.
3	Uehara T, Fujiwara T, Takeda K, Kunisada T, Ozaki T and Udono H: Immunotherapy for bone and soft tissue sarcomas. Biomed Res Int. 2015(820813)2015.PubMed/NCBI View Article : Google Scholar
4	Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, et al: Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm,open-label, phase 2 trial. Lancet Oncol. 18:1493–1501. 2017.PubMed/NCBI View Article : Google Scholar
5	D'Adamo DR, Anderson SE, Albritton K, Yamada J, Riedel E, Scheu K, Schwartz GK, Chen H and Maki RG: Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol. 23:7135–7142. 2005.PubMed/NCBI View Article : Google Scholar
6	Ruihua Xu: Medical Oncology. Bei Jing: People's Medical publishing house, 549-565, 2014 (In Chinese).
7	Yin QL, Wu D and Yu YY: Progression in anti-angiogenesis agents for soft tissue sarcoma. Chinese Clinical Oncol. 22:839–844. 2017.(In Chinese).
8	Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, et al: Pazopanib, a muhikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phaseIIstudy from the European organisatiou for research and treatment of eaneer-sofc tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 27:3126–3132. 2009.PubMed/NCBI View Article : Google Scholar
9	Van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, et al: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 379:1879–1886. 2012.PubMed/NCBI View Article : Google Scholar
10	In GK, Hu JS and Tseng WW: Treatment of abvanced, metastatic soft tissue sarcoma: Latest evidence and clinical considerations. Ther Adv Med Oncol. 9:533–550. 2017.PubMed/NCBI View Article : Google Scholar
11	Sarcoma Committee of Chinese Anti-Cancer Association; Chinese Society of Clinical Oncology. Chinese expert consensus on diagnosis and treatment of soft tissue sarcomas (Version 2015). Zhonghua Zhong Liu Za Zhi. 38:310–320. 2016.PubMed/NCBI View Article : Google Scholar : (In Chinese).
12	Chi Y, Fang Z, Hong X, Yao Y, Sun P, Wang G, Du F, Sun Y, Wu Q, Qu G, et al: Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. Clin Cancer Res 24: 5233-5238.
13	Paoluzzi L, Cacario A, Ghesani M, Karambelkar A, Rapkiewicz A, Weber J and Rosen G: Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res. 6(24)2016.PubMed/NCBI View Article : Google Scholar
14	Ben-Ami E, Barysauskas CM, Solomon S, Tahlil K, Malley R, Hohos M, Polson K, Loucks M, Severgnini M, Patel T, et al: Immunotherapy with single agent nivolumab foe advanced leiomyosarcoma of the uterus: Results of a phase 2 study. Cancer. 123:3285–3290. 2017.PubMed/NCBI View Article : Google Scholar
15	D'Angelo SP, Mahoaey MR, VanTine BA, Atkins J, Milhem MM, Jahagirdar BN, Antonescu CR, Horvath E, Tap WD, Schwartz GK and Streicher H: Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): Two open-label non-comparative, randomized,phase 2 trials. Lancet oncol. 19:416–426. 2018.PubMed/NCBI View Article : Google Scholar
16	Wagner MJ, Ricciotti RW, Mantilla J, Loggers ET, Pollack SM and Cranmer LD: Response to PD1 inhibition in conventional chondrosarcoma. J Immunother Cance. 6(94)2018.PubMed/NCBI View Article : Google Scholar
17	Linpeng Zhen, Luping Zhang, Zihan Xu, et al: Radiation therapy combined with immunological checkpoint inhibitors and distant effects. Chin J Lung Dis (Electronic Edition). 11:227–230. 2018.(In Chinese).
18	Zhouguang Hui, Meng Yuan and Yu Men: Application mechanism of radiotherapy combined with immune checkpiont inhibitors. Chin J Radiat Oncol. 27:875–879. 2018.(In Chinese).
19	Wang Q and Li B: Research progress in PD-1/PD-L1 monoclonal antibody combined with radiotherapy in treatment of solid tumors. Chin J Radiat Oncol. 25:1375–1378. 2016.(In Chinese).
20	Peng X and Zhou Q: First-line combination immunotherapy in advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 21:924–930. 2018.PubMed/NCBI View Article : Google Scholar : (In Chinese).
21	Zhang J, Zhang W, Qian Z, Gao B and Xiang Y: Tumor vascular normalization improves cancer treatment efficacy. China Oncology. 26:188–192. 2016.(In Chinese).
22	Xu Y, Zhang L and Jin L: Mechanism of tumor tolerance mediated hy immune microenvironment and its targeted therapy. J Int Oncol. 44:594–596. 2017.(In Chinese).
23	Zhang B and Yue H: The mechanisms of immune microenvironment in cancer development and progression. Modern Oncol. 23:862–864. 2015.(In Chinese).